参考文献/References:
[1] Guariguata L,Whiting DR,Hambleton I,et al.Global estimates of diabetes prevalence for 2013 and projections for 2035[J].Diabetes Res Clin Pract,2014,103(2):137-149.DOI:10.1016/j.diabres.2013.11.002.
[2] Russell-Jones D,Cuddihy RM,Hanefeld M,et al.Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes(DURATION-4): a 26-week double-blind study[J].Diabetes Care,2012,35(2):252-258.DOI:10.2337/dc11-1107.
[3] Hanefeld M,Pfützner A,Forst T,et al.Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study[J].Curr Med Res Opin,2006,22(6):1211-1215.DOI:10.1185/030079906X112598.
[4] Lennerz BS,Wabitsch M,Lippert H,et al.Bariatric surgery in adolescents and young adults--safety and effectiveness in a cohort of 345 patients[J].Int J Obes(Lond),2014,38(3):334-340.DOI:10.1038/ijo.2013.182.
[5] Xu W,Bi Y,Sun Z,et al.Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial(the CONFIDENCE study)[J].J Intern Med,2015,277(1):137-150.DOI:10.1111/joim.12293.
[6] Campbell IW,Mariz S.Beta-cell preservation with thiazolidinediones[J].Diabetes Res Clin Pract,2007,76(2):163-176.DOI:10.1016/j.diabres.2006.08.015.
[7] Azen SP,Peters RK,Berkowitz K,et al.TRIPOD(TRoglitazone In the Prevention Of Diabetes):a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus[J].Control Clin Trials,1998,19(2):217-231.
[8] Xiang AH,Peters RK,Kjos SL,et al.Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes[J].Diabetes,2006,55(2):517-522.DOI:10.2337/diabetes.55.02.06.db05-1066.
[9] Hanley AJ,Zinman B,Sheridan P,et al.Effect of rosiglitazone and ramipril on beta-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial[J].Diabetes Care,2010,33(3):608-613.DOI:10.2337/dc09-1579.
[10] DeFronzo RA,Tripathy D,Schwenke DC,et al.Pioglitazone for diabetes prevention in impaired glucose tolerance[J].N Engl J Med,2011,364(12):1104-1115.DOI:10.1056/NEJMoa1010949.
[11] Tripathy D,Schwenke DC,Banerji M,et al.Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: results from ACT NOW[J].J Clin Endocrinol Metab,2016,101(5):2056-2062.DOI:10.1210/jc.2015-4202.
[12] Kernan WN,Viscoli CM,Furie KL,et al.Pioglitazone after ischemic stroke or transient ischemic attack[J].N Engl J Med,2016,374(14):1321-1331.DOI:10.1056/NEJMoa1506930.
[13] Vaccaro O,Masulli M,Nicolucci A,et al.Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin(TOSCA.IT): a randomised, multicentre trial[J].Lancet Diabetes Endocrinol,2017,5(11):887-897. DOI:10.1016/S2213-8587(17)30317-0.
[14] Saremi A,Schwenke DC,Buchanan TA,et al.Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors[J].Arterioscler Thromb Vasc Biol,2013,33(2):393-399.DOI:10.1161/ATVBAHA.112.300346.
[15] Dormandy JA,Charbonnel B,Eckland DJ,et al.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial[J].Lancet,2005,366(9493):1279-1289.DOI:10.1016/S0140-6736(05)67528-9.
[16] Liao HW,Saver JL,Wu YL,et al.Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis[J].BMJ Open,2017,7(1):e013927.DOI:10.1136/bmjopen-2016-013927.
[17] Lincoff AM,Wolski K,Nicholls SJ,et al.Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials[J].JAMA,2007,298(10):1180-1188.DOI:10.1001/jama.298.10.1180.
[18] Caldwell SH,Hespenheide EE,Redick JA,et al.A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis[J].Am J Gastroenterol,2001,96(2):519-525.DOI:10.1111/j.1572-0241.2001.03553.x.
[19] Belfort R,Harrison SA,Brown K,et al.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[J].N Engl J Med,2006,355(22):2297-2307.DOI:10.1056/NEJMoa060326.
[20] Musso G,Cassader M,Paschetta E,et al.Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis[J].JAMA Intern Med,2017,177(5):633-640.DOI:10.1001/jamainternmed.2016.9607.
[21] Sangeeta S.Metformin and pioglitazone in polycystic ovarian syndrome: a comparative study[J].J Obstet Gynaecol India,2012,62(5):551-556.DOI:10.1007/s13224-012-0183-3.
[22] Shahebrahimi K,Jalilian N,Bazgir N,et al.Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome[J].Indian J Endocrinol Metab,2016,20(6):805-809.DOI:10.4103/2230-8210.192925.
[23] Okumura T.Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs[J].J Gastroenterol,2010,45(11):1097-1102.DOI:10.1007/s00535-010-0310-9.
[24] Colin C,Salamone S,Grillier-Vuissoz I,et al.New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines[J].Breast Cancer Res Treat,2010,124(1):101-110.DOI:10.1007/s10549-009-0700-y.
[25] Bénit P,Pelhaître A,Saunier E,et al.Paradoxical inhibition of glycolysis by pioglitazone opposes the mitochondriopathy caused by AIF deficiency[J].EBioMedicine,2017,17:75-87.DOI:10.1016/j.ebiom.2017.02.013.
[26] Tuccori M,Filion KB,Yin H,et al.Pioglitazone use and risk of bladder cancer: population based cohort study[J].BMJ,2016,352:i1541.DOI:10.1136/bmj.i1541.
[27] Levin D,Bell S,Sund R,et al.Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis[J].Diabetologia,2015,58(3):493-504.DOI:10.1007/s00125-014-3456-9.
[28] Lin HC,Hsu YT,Kachingwe BH,et al.Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study[J].J Clin Pharm Ther,2014,39(4):354-360.DOI:10.1111/jcpt.12151.
[29] Home PD,Pocock SJ,Beck-Nielsen H,et al.Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes(RECORD):a multicentre, randomised, open-label trial[J].Lancet,2009,373(9681):2125-2135.DOI:10.1016/S0140-6736(09)60953-3.
[30] Schöndorf T,Musholt PB,Hohberg C,et al.The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study[J].J Diabetes Sci Technol,2011,5(2):426-432. DOI:10.1177/193229681100500233.
[31] Albertini JP,McMorn SO,Chen H,et al.Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus[J].Atherosclerosis,2007,195(1):e159-e166.DOI:10.1016/j.atherosclerosis.2007.01.003.
[32] Rizos CV,Kei A,Elisaf MS.The current role of thiazolidinediones in diabetes management[J].Arch Toxicol,2016,90(8):1861-1881.DOI:10.1007/s00204-016-1737-4.
[33] Giovannucci E,Harlan DM,Archer MC,et al.Diabetes and cancer: a consensus report[J].CA Cancer J Clin,2010,60(4):207-221. DOI:10.3322/caac.20078.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(04):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(04):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(04):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(04):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病
患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]